[{"edinetCode":"E00942","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6635.0,"averageTemporaryStaff":1479.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":40594000.0,"sharesOwendPercent":0.3442,"outstandingShares":null,"numberOfSubsidiary":36.0,"bps":1030.96,"equityRatio":0.647,"cashAndCashEquivalents":23466000000.0,"assets":181543000000.0,"currentAssets":100948000000.0,"fixedAsset":80594000000.0,"tangibleFixedAssets":45834000000.0,"intangibleFixedAssets":2663000000.0,"investmentAndOtherAssets":32096000000.0,"liabilities":63107000000.0,"currentLiabilities":53422000000.0,"shorTermDept":3353000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":9684000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1765000000.0,"netAsset":118436000000.0,"capitalStock":113517000000.0,"capital":6415000000.0,"capitalSurplus":5737000000.0,"accumulatedEarnings":106302000000.0,"treasuryStock":-4938000000.0,"valuationAndConversionAdjustments":3924000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":154599000000.0,"costOfSales":63254000000.0,"grossProfit":91344000000.0,"sgaExpenses":75893000000.0,"salaryAndBenefit":null,"depreciationAndSGA":985000000.0,"RDExpenses":6123000000.0,"operatingIncome":15451000000.0,"nonOperatingIncome":1135000000.0,"nonOperatingExpenses":623000000.0,"interestExpense":135000000.0,"ordinaryProfit":15964000000.0,"extraordinaryGain":1329000000.0,"extraordinaryLoss":2541000000.0,"incomeBeforeTax":14752000000.0,"incomeTaxes":4738000000.0,"netIncome":10013000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":10011000000.0,"comprehensiveIncome":9305000000.0,"eps":87.95,"dilutedEps":87.57,"dividendPerShare":null,"per":23.7,"roe":0.088,"cashFlowFromOperatingActivities":13428000000.0,"depreciationAndCashflowFromOperatingActivities":5552000000.0,"cashFlowFromInvestingActivities":-9511000000.0,"cashFlowFromFinancialActivities":-2335000000.0,"changesInCashAndCashEquivalents":947000000.0,"列1":"asr","submitDate":"2017\/6\/26","stockCode":4527,"accountingYear":"第81期(自　平成28年４月１日　至　平成29年３月31日)","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6448.0,"averageTemporaryStaff":1698.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":40118000.0,"sharesOwendPercent":0.3521,"outstandingShares":null,"numberOfSubsidiary":39.0,"bps":1115.94,"equityRatio":0.633,"cashAndCashEquivalents":30063000000.0,"assets":200836000000.0,"currentAssets":114428000000.0,"fixedAsset":86407000000.0,"tangibleFixedAssets":47193000000.0,"intangibleFixedAssets":4108000000.0,"investmentAndOtherAssets":35106000000.0,"liabilities":72395000000.0,"currentLiabilities":61464000000.0,"shorTermDept":4151000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":10931000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1702000000.0,"netAsset":128440000000.0,"capitalStock":119915000000.0,"capital":6415000000.0,"capitalSurplus":5737000000.0,"accumulatedEarnings":112696000000.0,"treasuryStock":-4935000000.0,"valuationAndConversionAdjustments":7209000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":171742000000.0,"costOfSales":70746000000.0,"grossProfit":100996000000.0,"sgaExpenses":81962000000.0,"salaryAndBenefit":null,"depreciationAndSGA":982000000.0,"RDExpenses":6553000000.0,"operatingIncome":19087000000.0,"nonOperatingIncome":998000000.0,"nonOperatingExpenses":1236000000.0,"interestExpense":143000000.0,"ordinaryProfit":18849000000.0,"extraordinaryGain":null,"extraordinaryLoss":2028000000.0,"incomeBeforeTax":16820000000.0,"incomeTaxes":7483000000.0,"netIncome":9336000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":9289000000.0,"comprehensiveIncome":12167000000.0,"eps":81.55,"dilutedEps":81.2,"dividendPerShare":null,"per":36.5,"roe":0.076,"cashFlowFromOperatingActivities":19154000000.0,"depreciationAndCashflowFromOperatingActivities":5593000000.0,"cashFlowFromInvestingActivities":-11014000000.0,"cashFlowFromFinancialActivities":-1823000000.0,"changesInCashAndCashEquivalents":6125000000.0,"列1":"asr","submitDate":"2018\/6\/25","stockCode":4527,"accountingYear":"第82期(自　2017年４月１日　至　2018年３月31日)","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6355.0,"averageTemporaryStaff":1657.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":42357000.0,"sharesOwendPercent":0.3716,"outstandingShares":null,"numberOfSubsidiary":39.0,"bps":1147.42,"equityRatio":0.651,"cashAndCashEquivalents":37345000000.0,"assets":200953000000.0,"currentAssets":116402000000.0,"fixedAsset":84550000000.0,"tangibleFixedAssets":47421000000.0,"intangibleFixedAssets":3565000000.0,"investmentAndOtherAssets":33563000000.0,"liabilities":68764000000.0,"currentLiabilities":60760000000.0,"shorTermDept":3745000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":8004000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1424000000.0,"netAsset":132189000000.0,"capitalStock":127105000000.0,"capital":6446000000.0,"capitalSurplus":5603000000.0,"accumulatedEarnings":119989000000.0,"treasuryStock":-4935000000.0,"valuationAndConversionAdjustments":3667000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":183582000000.0,"costOfSales":74048000000.0,"grossProfit":109533000000.0,"sgaExpenses":88812000000.0,"salaryAndBenefit":null,"depreciationAndSGA":1134000000.0,"RDExpenses":6831000000.0,"operatingIncome":20812000000.0,"nonOperatingIncome":1200000000.0,"nonOperatingExpenses":3042000000.0,"interestExpense":148000000.0,"ordinaryProfit":18970000000.0,"extraordinaryGain":null,"extraordinaryLoss":2669000000.0,"incomeBeforeTax":16300000000.0,"incomeTaxes":6481000000.0,"netIncome":9818000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":9799000000.0,"comprehensiveIncome":6138000000.0,"eps":86.0,"dilutedEps":85.66,"dividendPerShare":null,"per":33.0,"roe":0.076,"cashFlowFromOperatingActivities":21745000000.0,"depreciationAndCashflowFromOperatingActivities":6159000000.0,"cashFlowFromInvestingActivities":-10245000000.0,"cashFlowFromFinancialActivities":-3386000000.0,"changesInCashAndCashEquivalents":7281000000.0,"列1":"asr","submitDate":"2019\/6\/28","stockCode":4527,"accountingYear":"第83期(自　2018年４月１日　至　2019年３月31日)","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.67,"cashAndCashEquivalents":null,"assets":194435000000.0,"currentAssets":111164000000.0,"fixedAsset":83271000000.0,"tangibleFixedAssets":46270000000.0,"intangibleFixedAssets":3880000000.0,"investmentAndOtherAssets":33120000000.0,"liabilities":62692000000.0,"currentLiabilities":54658000000.0,"shorTermDept":3183000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":8034000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1224000000.0,"netAsset":131742000000.0,"capitalStock":127377000000.0,"capital":6446000000.0,"capitalSurplus":5603000000.0,"accumulatedEarnings":120261000000.0,"treasuryStock":-4935000000.0,"valuationAndConversionAdjustments":2934000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":41910000000.0,"costOfSales":17551000000.0,"grossProfit":24359000000.0,"sgaExpenses":20438000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3860000000.0,"nonOperatingIncome":459000000.0,"nonOperatingExpenses":395000000.0,"interestExpense":33000000.0,"ordinaryProfit":3924000000.0,"extraordinaryGain":153000000.0,"extraordinaryLoss":894000000.0,"incomeBeforeTax":3183000000.0,"incomeTaxes":959000000.0,"netIncome":2224000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2217000000.0,"comprehensiveIncome":1498000000.0,"eps":19.46,"dilutedEps":19.38,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4527,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":45517000.0,"sharesOwendPercent":0.399,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.67,"cashAndCashEquivalents":37062000000.0,"assets":199469000000.0,"currentAssets":115314000000.0,"fixedAsset":84155000000.0,"tangibleFixedAssets":46082000000.0,"intangibleFixedAssets":3910000000.0,"investmentAndOtherAssets":34162000000.0,"liabilities":64463000000.0,"currentLiabilities":56024000000.0,"shorTermDept":1716000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":8439000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1424000000.0,"netAsset":135006000000.0,"capitalStock":132579000000.0,"capital":6504000000.0,"capitalSurplus":5661000000.0,"accumulatedEarnings":125349000000.0,"treasuryStock":-4935000000.0,"valuationAndConversionAdjustments":1111000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":90428000000.0,"costOfSales":36812000000.0,"grossProfit":53615000000.0,"sgaExpenses":43172000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":10393000000.0,"nonOperatingIncome":907000000.0,"nonOperatingExpenses":417000000.0,"interestExpense":64000000.0,"ordinaryProfit":10883000000.0,"extraordinaryGain":153000000.0,"extraordinaryLoss":558000000.0,"incomeBeforeTax":10478000000.0,"incomeTaxes":3149000000.0,"netIncome":7329000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":7305000000.0,"comprehensiveIncome":4762000000.0,"eps":64.07,"dilutedEps":63.86,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":7464000000.0,"depreciationAndCashflowFromOperatingActivities":2864000000.0,"cashFlowFromInvestingActivities":-2457000000.0,"cashFlowFromFinancialActivities":-3709000000.0,"changesInCashAndCashEquivalents":-282000000.0,"列1":"q2r","submitDate":"2019\/11\/14","stockCode":4527,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.669,"cashAndCashEquivalents":null,"assets":204673000000.0,"currentAssets":123158000000.0,"fixedAsset":81515000000.0,"tangibleFixedAssets":45749000000.0,"intangibleFixedAssets":3685000000.0,"investmentAndOtherAssets":32080000000.0,"liabilities":66496000000.0,"currentLiabilities":57941000000.0,"shorTermDept":1950000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":8554000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1372000000.0,"netAsset":138177000000.0,"capitalStock":136354000000.0,"capital":6504000000.0,"capitalSurplus":5661000000.0,"accumulatedEarnings":129124000000.0,"treasuryStock":-4935000000.0,"valuationAndConversionAdjustments":552000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":138119000000.0,"costOfSales":55175000000.0,"grossProfit":82944000000.0,"sgaExpenses":64717000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":18126000000.0,"nonOperatingIncome":1353000000.0,"nonOperatingExpenses":1408000000.0,"interestExpense":95000000.0,"ordinaryProfit":18072000000.0,"extraordinaryGain":1581000000.0,"extraordinaryLoss":690000000.0,"incomeBeforeTax":18962000000.0,"incomeTaxes":6353000000.0,"netIncome":12609000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":12562000000.0,"comprehensiveIncome":9434000000.0,"eps":110.17,"dilutedEps":109.82,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/13","stockCode":4527,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6619.0,"averageTemporaryStaff":1591.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":47628000.0,"sharesOwendPercent":0.4175,"outstandingShares":null,"numberOfSubsidiary":41.0,"bps":1217.67,"equityRatio":0.645,"cashAndCashEquivalents":44665000000.0,"assets":215301000000.0,"currentAssets":130108000000.0,"fixedAsset":85192000000.0,"tangibleFixedAssets":48460000000.0,"intangibleFixedAssets":5318000000.0,"investmentAndOtherAssets":31413000000.0,"liabilities":75269000000.0,"currentLiabilities":62117000000.0,"shorTermDept":2105000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":13151000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5190000000.0,"netAsset":140032000000.0,"capitalStock":139215000000.0,"capital":6504000000.0,"capitalSurplus":5661000000.0,"accumulatedEarnings":131985000000.0,"treasuryStock":-4935000000.0,"valuationAndConversionAdjustments":-316000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":188327000000.0,"costOfSales":74135000000.0,"grossProfit":114192000000.0,"sgaExpenses":91154000000.0,"salaryAndBenefit":null,"depreciationAndSGA":1226000000.0,"RDExpenses":7050000000.0,"operatingIncome":23085000000.0,"nonOperatingIncome":1607000000.0,"nonOperatingExpenses":1958000000.0,"interestExpense":125000000.0,"ordinaryProfit":22735000000.0,"extraordinaryGain":2237000000.0,"extraordinaryLoss":3241000000.0,"incomeBeforeTax":21730000000.0,"incomeTaxes":6448000000.0,"netIncome":15282000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":15410000000.0,"comprehensiveIncome":11275000000.0,"eps":135.13,"dilutedEps":134.71,"dividendPerShare":null,"per":21.9,"roe":0.114,"cashFlowFromOperatingActivities":19040000000.0,"depreciationAndCashflowFromOperatingActivities":6058000000.0,"cashFlowFromInvestingActivities":-9405000000.0,"cashFlowFromFinancialActivities":-1603000000.0,"changesInCashAndCashEquivalents":7250000000.0,"列1":"asr","submitDate":"2020\/6\/29","stockCode":4527,"accountingYear":"第84期(自　2019年４月１日　至　2020年３月31日)","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.669,"cashAndCashEquivalents":null,"assets":206492000000.0,"currentAssets":122074000000.0,"fixedAsset":84418000000.0,"tangibleFixedAssets":47982000000.0,"intangibleFixedAssets":5023000000.0,"investmentAndOtherAssets":31412000000.0,"liabilities":67223000000.0,"currentLiabilities":54050000000.0,"shorTermDept":2463000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":13172000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5224000000.0,"netAsset":139269000000.0,"capitalStock":139670000000.0,"capital":6504000000.0,"capitalSurplus":5661000000.0,"accumulatedEarnings":132440000000.0,"treasuryStock":-4935000000.0,"valuationAndConversionAdjustments":-1446000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":38641000000.0,"costOfSales":16412000000.0,"grossProfit":22229000000.0,"sgaExpenses":18483000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3878000000.0,"nonOperatingIncome":473000000.0,"nonOperatingExpenses":246000000.0,"interestExpense":32000000.0,"ordinaryProfit":4105000000.0,"extraordinaryGain":null,"extraordinaryLoss":1112000000.0,"incomeBeforeTax":2992000000.0,"incomeTaxes":1045000000.0,"netIncome":1947000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1937000000.0,"comprehensiveIncome":721000000.0,"eps":16.99,"dilutedEps":16.94,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/12","stockCode":4527,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":46974000.0,"sharesOwendPercent":0.4118,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.667,"cashAndCashEquivalents":46397000000.0,"assets":214788000000.0,"currentAssets":129415000000.0,"fixedAsset":85373000000.0,"tangibleFixedAssets":48584000000.0,"intangibleFixedAssets":4952000000.0,"investmentAndOtherAssets":31836000000.0,"liabilities":70477000000.0,"currentLiabilities":55727000000.0,"shorTermDept":2574000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":14750000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":6672000000.0,"netAsset":144310000000.0,"capitalStock":143911000000.0,"capital":6504000000.0,"capitalSurplus":5661000000.0,"accumulatedEarnings":136681000000.0,"treasuryStock":-4935000000.0,"valuationAndConversionAdjustments":-651000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":83004000000.0,"costOfSales":34046000000.0,"grossProfit":48957000000.0,"sgaExpenses":38228000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":10779000000.0,"nonOperatingIncome":878000000.0,"nonOperatingExpenses":567000000.0,"interestExpense":65000000.0,"ordinaryProfit":11090000000.0,"extraordinaryGain":null,"extraordinaryLoss":2040000000.0,"incomeBeforeTax":9050000000.0,"incomeTaxes":2864000000.0,"netIncome":6186000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6178000000.0,"comprehensiveIncome":5765000000.0,"eps":54.17,"dilutedEps":54.01,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":6586000000.0,"depreciationAndCashflowFromOperatingActivities":2943000000.0,"cashFlowFromInvestingActivities":-4309000000.0,"cashFlowFromFinancialActivities":398000000.0,"changesInCashAndCashEquivalents":1731000000.0,"列1":"q2r","submitDate":"2020\/11\/13","stockCode":4527,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.682,"cashAndCashEquivalents":null,"assets":215226000000.0,"currentAssets":128512000000.0,"fixedAsset":86714000000.0,"tangibleFixedAssets":49447000000.0,"intangibleFixedAssets":5820000000.0,"investmentAndOtherAssets":31446000000.0,"liabilities":67453000000.0,"currentLiabilities":53308000000.0,"shorTermDept":2341000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":14145000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":6334000000.0,"netAsset":147772000000.0,"capitalStock":147287000000.0,"capital":6504000000.0,"capitalSurplus":5661000000.0,"accumulatedEarnings":140057000000.0,"treasuryStock":-4936000000.0,"valuationAndConversionAdjustments":-558000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":129611000000.0,"costOfSales":52910000000.0,"grossProfit":76701000000.0,"sgaExpenses":59699000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":17062000000.0,"nonOperatingIncome":1398000000.0,"nonOperatingExpenses":1034000000.0,"interestExpense":97000000.0,"ordinaryProfit":17426000000.0,"extraordinaryGain":2791000000.0,"extraordinaryLoss":3192000000.0,"incomeBeforeTax":17024000000.0,"incomeTaxes":5927000000.0,"netIncome":11097000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":11083000000.0,"comprehensiveIncome":10757000000.0,"eps":97.16,"dilutedEps":96.88,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/12","stockCode":4527,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6596.0,"averageTemporaryStaff":1477.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":46197000.0,"sharesOwendPercent":0.405,"outstandingShares":null,"numberOfSubsidiary":45.0,"bps":1363.42,"equityRatio":0.689,"cashAndCashEquivalents":52254000000.0,"assets":225790000000.0,"currentAssets":133071000000.0,"fixedAsset":92719000000.0,"tangibleFixedAssets":49790000000.0,"intangibleFixedAssets":7535000000.0,"investmentAndOtherAssets":35392000000.0,"liabilities":69178000000.0,"currentLiabilities":56471000000.0,"shorTermDept":2312000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":12707000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5787000000.0,"netAsset":156612000000.0,"capitalStock":152741000000.0,"capital":6504000000.0,"capitalSurplus":5661000000.0,"accumulatedEarnings":145511000000.0,"treasuryStock":-4936000000.0,"valuationAndConversionAdjustments":2784000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":181287000000.0,"costOfSales":74326000000.0,"grossProfit":106960000000.0,"sgaExpenses":83736000000.0,"salaryAndBenefit":null,"depreciationAndSGA":1438000000.0,"RDExpenses":7903000000.0,"operatingIncome":22990000000.0,"nonOperatingIncome":2639000000.0,"nonOperatingExpenses":1718000000.0,"interestExpense":145000000.0,"ordinaryProfit":23910000000.0,"extraordinaryGain":2791000000.0,"extraordinaryLoss":3695000000.0,"incomeBeforeTax":23006000000.0,"incomeTaxes":6236000000.0,"netIncome":16770000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":16743000000.0,"comprehensiveIncome":19794000000.0,"eps":146.78,"dilutedEps":146.36,"dividendPerShare":null,"per":20.1,"roe":0.117,"cashFlowFromOperatingActivities":20008000000.0,"depreciationAndCashflowFromOperatingActivities":6376000000.0,"cashFlowFromInvestingActivities":-10237000000.0,"cashFlowFromFinancialActivities":-2347000000.0,"changesInCashAndCashEquivalents":7519000000.0,"列1":"asr","submitDate":"2021\/6\/25","stockCode":4527,"accountingYear":"第85期(自　2020年４月１日　至　2021年３月31日)","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.689,"cashAndCashEquivalents":null,"assets":232431000000.0,"currentAssets":135087000000.0,"fixedAsset":97343000000.0,"tangibleFixedAssets":51703000000.0,"intangibleFixedAssets":7447000000.0,"investmentAndOtherAssets":38193000000.0,"liabilities":71264000000.0,"currentLiabilities":57202000000.0,"shorTermDept":2934000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":14062000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":7114000000.0,"netAsset":161166000000.0,"capitalStock":154849000000.0,"capital":6504000000.0,"capitalSurplus":5661000000.0,"accumulatedEarnings":147619000000.0,"treasuryStock":-4936000000.0,"valuationAndConversionAdjustments":5187000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":42315000000.0,"costOfSales":18188000000.0,"grossProfit":24126000000.0,"sgaExpenses":18118000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":6008000000.0,"nonOperatingIncome":920000000.0,"nonOperatingExpenses":407000000.0,"interestExpense":32000000.0,"ordinaryProfit":6521000000.0,"extraordinaryGain":null,"extraordinaryLoss":109000000.0,"incomeBeforeTax":6411000000.0,"incomeTaxes":1661000000.0,"netIncome":4750000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4731000000.0,"comprehensiveIncome":7176000000.0,"eps":41.48,"dilutedEps":41.36,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/11","stockCode":4527,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":50952000.0,"sharesOwendPercent":0.4467,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.635,"cashAndCashEquivalents":68569000000.0,"assets":261458000000.0,"currentAssets":155278000000.0,"fixedAsset":106180000000.0,"tangibleFixedAssets":59916000000.0,"intangibleFixedAssets":7318000000.0,"investmentAndOtherAssets":38945000000.0,"liabilities":88891000000.0,"currentLiabilities":74723000000.0,"shorTermDept":5490000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":14167000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":9326000000.0,"netAsset":172567000000.0,"capitalStock":160874000000.0,"capital":6504000000.0,"capitalSurplus":5661000000.0,"accumulatedEarnings":153644000000.0,"treasuryStock":-4936000000.0,"valuationAndConversionAdjustments":5227000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":91019000000.0,"costOfSales":38557000000.0,"grossProfit":52461000000.0,"sgaExpenses":38689000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":13771000000.0,"nonOperatingIncome":930000000.0,"nonOperatingExpenses":1188000000.0,"interestExpense":73000000.0,"ordinaryProfit":13514000000.0,"extraordinaryGain":507000000.0,"extraordinaryLoss":182000000.0,"incomeBeforeTax":13840000000.0,"incomeTaxes":3041000000.0,"netIncome":10798000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":10756000000.0,"comprehensiveIncome":13306000000.0,"eps":94.3,"dilutedEps":94.03,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":12005000000.0,"depreciationAndCashflowFromOperatingActivities":3209000000.0,"cashFlowFromInvestingActivities":3023000000.0,"cashFlowFromFinancialActivities":-754000000.0,"changesInCashAndCashEquivalents":16314000000.0,"列1":"q2r","submitDate":"2021\/11\/12","stockCode":4527,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0},{"edinetCode":"E00942","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.645,"cashAndCashEquivalents":null,"assets":265056000000.0,"currentAssets":157877000000.0,"fixedAsset":107178000000.0,"tangibleFixedAssets":60001000000.0,"intangibleFixedAssets":9324000000.0,"investmentAndOtherAssets":37852000000.0,"liabilities":87660000000.0,"currentLiabilities":69786000000.0,"shorTermDept":7454000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":17873000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":12982000000.0,"netAsset":177395000000.0,"capitalStock":165460000000.0,"capital":6504000000.0,"capitalSurplus":5781000000.0,"accumulatedEarnings":158110000000.0,"treasuryStock":-4936000000.0,"valuationAndConversionAdjustments":5568000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":144022000000.0,"costOfSales":60028000000.0,"grossProfit":83993000000.0,"sgaExpenses":60445000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":23548000000.0,"nonOperatingIncome":1543000000.0,"nonOperatingExpenses":1351000000.0,"interestExpense":118000000.0,"ordinaryProfit":23740000000.0,"extraordinaryGain":507000000.0,"extraordinaryLoss":698000000.0,"incomeBeforeTax":23549000000.0,"incomeTaxes":6451000000.0,"netIncome":17098000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":16933000000.0,"comprehensiveIncome":19897000000.0,"eps":148.45,"dilutedEps":148.02,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/14","stockCode":4527,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00942","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":6441,"settlementDate":"2022\/3\/31","submitterName":"ロート製薬株式会社","submitterNameEnglish":"ROHTO PHARMACEUTICAL CO.,LTD.","submitterNameKana":"ロートセイヤクカブシキガイシャ","location":"大阪市生野区巽西１丁目８番１号","industory":"医薬品","corporateNumber":6120000000000.0}]